AQ 13

Drug Profile

AQ 13

Alternative Names: Aminoquinolone-13; AQ-13

Latest Information Update: 27 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institutes of Health (USA); Tulane University
  • Developer Immtech Pharmaceuticals
  • Class Aminoquinolines; Antimalarials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 10 Feb 2006 Tulane University has granted Immtech International an exclusive license to develop, manufacture and commercialise aminoquinolones, including AQ 13, for the treatment, prophylaxis and diagnosis of infectious diseases
  • 18 Dec 2003 Data presented at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH-2003) have been added to the pharmacokinetics section ,,
  • 26 Apr 2000 Phase-I clinical trials for Malaria in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top